LOCAMETZ (gallium ga-68 gozetotide)
Locametz is a radioactive diagnostic agent used during PET scans to identify prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. It helps clinicians evaluate patients with suspected metastasis before they begin initial therapy or those with rising PSA levels that suggest the cancer has returned. Additionally, this tool helps identify which patients are suitable candidates for targeted PSMA-directed therapies.
How LOCAMETZ Works
This agent works by binding to PSMA, a protein frequently found in high amounts on the surface of malignant prostate cancer cells. Because it contains gallium-68, a radionuclide that emits positrons, it allows for the visualization of these cancer cells through PET imaging.
Details
- Status
- Prescription
- First Approved
- 2022-03-23
- Patent Cliff
- 2036
- Routes
- INTRAVENOUS
- Dosage Forms
- POWDER
LOCAMETZ Approval History
What LOCAMETZ Treats
3 indicationsLOCAMETZ is approved for 3 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Prostate Cancer
- Metastasis
- Recurrence
LOCAMETZ Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in LOCAMETZ's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications LOCAMETZ treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to LOCAMETZ
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LOCAMETZ FDA Label Details
Indications & Usage
FDA Label (PDF)LOCAMETZ is indicated for the treatment of Prostate Cancer; Metastasis; Recurrence.
LOCAMETZ Patents & Exclusivity
Patents (2 active)
Pro Intelligence Preview
Deep insights for LOCAMETZ
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2036
- • 2 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.